The 3′,5′ Cyclic AMP Phosphodiesterase pipeline drugs market research report outlays comprehensive information on the 3′,5′ Cyclic AMP Phosphodiesterase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the 3′,5′ Cyclic AMP Phosphodiesterase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Respiratory, Central Nervous System, and Dermatology which include the indications Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Chronic Obstructive Pulmonary Disease (COPD), Asthma, Alzheimer’s Disease, Alcohol Dependence, Atopic Dermatitis (Atopic Eczema), and Rosacea. It also reviews key players involved in 3′,5′ Cyclic AMP Phosphodiesterase targeted therapeutics development with respective active and dormant or discontinued products.
The 3′,5′ Cyclic AMP Phosphodiesterase pipeline targets constitutes close to 57 molecules. Out of which, approximately 48 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 9, 10, 4, 4, 13, and 5 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 5, and 3 molecule.
3′,5′ Cyclic AMP Phosphodiesterase overview
3′,5′-cyclic AMP (cAMP) phosphodiesterase (PDE) are enzymes that catalyze the hydrolysis of the 3′ cyclic phosphate bond of cyclic nucleotides. Phosphodiesterases are enzymes that regulate the intracellular levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate. 11 PDE gene families have been identified, based on their amino acid sequences, biochemical properties, and inhibitor profiles. Different PDEs can share the same catalytic function, but may differ in tissue expression and intracellular localization.
For a complete picture of 3′,5′ Cyclic AMP Phosphodiesterase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
